Pharma M&A and Pharma Divestment
PharmaVenture's M&A professionals work closely with clients to achieve their strategic objectives and to derive optimal value from their pharma M&A transactions whilst respecting the different requirements of shareholders, management and other stakeholders. Our multi-disciplinary team is composed of experienced advisors with an industry, investment banking or strategy consulting background, who have extensive international experience.
We are specialists in conducting custom made sale process for companies, products or other assets such as manufacturing sites, across a wide range of sub-sectors including pharmaceuticals, medical devices, diagnostics, contract services and imaging systems. Our healthcare industry knowledge makes us uniquely sensitive to the key issues in company sales and asset divestments, allowing us to actively manage the sale process through to legal completion. Combining the deep strategic and commercial experience of our healthcare sector specialists with the extensive experience of our seasoned life sciences mergers and acquisitions professionals optimises the price, form of consideration and structure of your sale process.
We also specialise in buy-side transactions, either for companies or assets, such as pharmaceutical products. PharmaVentures’ well conceived and highly structured asset searches are complemented by our wide ranging industry presence that ensures a consistent flow of attractive acquisition opportunities. Our experience in developing your proposition combines well with existing relationships and networks with key personnel across a broad group of potential trade and private equity vendors that ensures our confidential approach is well received.
We also advise purely on exit strategy, giving vendors and other stakeholders a dispassionate view of the achievable value of assets under consideration, where they might eventually be sold and how the roadmap to those potential acquirers should be followed. We operate at the individual product level for the smallest of innovator companies, all the way up to the divestment of large subsidiaries of major corporations.